title: EBV-B cells as antigen presenting cells in characterization of the self/donor context of allorecognition by T lymphocytes.
abstract: Alloreactivity is caused by T cell recognition of foreign histocompatibility antigens according to two models: (i) indirect recognition, in which processed allogeneic antigens are presented by self-major histocompatibility complexes like any other foreign antigen, and (ii) direct recognition, where the foreign MHC itself is recognized breaking the T cell recognition rule of self-restriction. This paper uses these two cases of alloantigen presentation as illustrative examples to investigate (i) the capacity of Epstein-Barr virus-transformed B cells (EBV-B cells) to process alloantigens, and (ii) in vitro assays with EBV-B cell lysate as a source of alloantigen, in order to characterize alloreactive T cell populations. A microculture system was established using donor EBV-B cell lysate as a source of the allogeneic antigen and donor or recipient EBV-B cells as antigen presenting cells to investigate whether alloantigen is recognized by effector T cells from the recipient. T lymphocytes produced after expansion in the presence of interleukin-2 from four samples of liver biopsies (three patients) and four samples of bronchoalveolar lavages (four patients) were used as effector cells. Upon human leucocyte antigen class II typing, these expressed the patient phenotype. When the T lymphocytes were from liver grafts, the recognition involved donor antigens presented by donor EBV-B cells (direct recognition). On the other hand, when the T lymphocytes were cultured from lung grafts, they mainly recognized antigens of donor EBV-B cell lysates in a self-restricted context (indirect recognition). These data suggest that EBV-B cells can provide allogeneic determinants recognized by T cells in donor or self-contexts, i.e. through either direct or indirect recognition.
authors.affiliation: Laboratoire d'Immunologie, Hôpital Sud, CHU de Grenoble, France. Christian.Drouet@ujf-grenoble.fr
authors.forename: C
authors.initials: C
authors.lastname: Drouet
authors.forename: C
authors.initials: C
authors.lastname: Arvieux
authors.forename: G
authors.initials: G
authors.lastname: Devouassoux
authors.forename: F
authors.initials: F
authors.lastname: Csopaki
authors.forename: O
authors.initials: O
authors.lastname: Chavanon
authors.forename: P Y
authors.initials: PY
authors.lastname: Brichon
authors.forename: C
authors.initials: C
authors.lastname: Letoublon
authors.forename: J P
authors.initials: JP
authors.lastname: Zarski
authors.forename: D
authors.initials: D
authors.lastname: Barnoud
authors.forename: C
authors.initials: C
authors.lastname: Pison
mesh_terms: D000328:Adult; D001402:B-Lymphocytes / Q000276:immunology*; D018893:Bronchoalveolar Lavage; D002461:Cell Line, Transformed; D002472:Cell Transformation, Viral; D002478:Cells, Cultured; D005260:Female; D004854:Herpesvirus 4, Human; D006801:Humans; D007376:Interleukin-2 / Q000494:pharmacology; D007519:Isoantigens / Q000276:immunology*; D008099:Liver / Q000166:cytology / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology*; D016040:Lung Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000494:pharmacology; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D007376:Interleukin-2; D007519:Isoantigens; D011994:Recombinant Proteins